UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Brain (London, England : 1878), 2019-07, Vol.142 (7), p.1894-1904

2019

Volltextzugriff (PDF)

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

BMC neurology, 2019-08, Vol.19 (1), p.191-8, Article 191

2019

Volltextzugriff (PDF)

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia

Psychosomatics (Washington, D.C.), 2016-03, Vol.57 (2), p.208-216

2016

Volltextzugriff (PDF)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2019, Vol.5 (1), p.328-337

2019

Volltextzugriff (PDF)

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

Current medical research and opinion, 2012-03, Vol.28 (3), p.315-323

2012

Volltextzugriff (PDF)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

BMC psychiatry, 2014-01, Vol.14 (1), p.7-7, Article 7

2014

Volltextzugriff (PDF)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

Alzheimer's & dementia : translational research & clinical interventions, 2018, Vol.4 (1), p.652-660

2018

Volltextzugriff (PDF)

Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy

Current medical research and opinion, 2013-11, Vol.29 (11), p.1533-1537

2013

Volltextzugriff (PDF)

112-GHz, 157-GHz, and 180-GHz InP HEMT traveling-wave amplifiers

IEEE transactions on microwave theory and techniques, 1998-12, Vol.46 (12), p.2553-2559

1998

Volltextzugriff (PDF)

A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression

The journal of clinical psychiatry, 2006-05, Vol.67 (5), p.798-806

2006

Volltextzugriff (PDF)

Comparison of Neuroimaging Modalities for the Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Dementia

The American journal of geriatric psychiatry, 2013-03, Vol.21 (3), p.S137-S137

2013

Volltextzugriff (PDF)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Patient preference and adherence, 2011-01, Vol.5 (default), p.547-554

2011

Volltextzugriff (PDF)

Neuroimaging Results and A4 in the Context of the LEARN Study

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Volltextzugriff (PDF)

Architecture, design, and test of continuous-time tunable intermediate-frequency bandpass delta-sigma modulators

IEEE journal of solid-state circuits, 2001-01, Vol.36 (1), p.5-13

2001

Volltextzugriff (PDF)

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P37-P38

2017

Volltextzugriff (PDF)

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P605-P605

2017

Volltextzugriff (PDF)

PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1452-P1452

2017

Volltextzugriff (PDF)

DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1260-P1260

2017

Volltextzugriff (PDF)

SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER’S DISEASE DEMENTIA

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P251-P252

2017

Volltextzugriff (PDF)

SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P254-P255

2017

Volltextzugriff (PDF)

A 60-watt X-band spatially combined solid-state amplifier

1999 IEEE MTT-S International Microwave Symposium Digest (Cat. No.99CH36282), 1999, Vol.2, p.539-542 vol.2

1999

Volltextzugriff (PDF)

Reply to Pharmacokinetic Drug-Drug Interactions Between Olanzapine and Valproate Need to Be Better Studied

The journal of clinical psychiatry, 2010-07, Vol.71 (7), p.958-959

2010

Volltextzugriff (PDF)

Active and nonlinear wave propagation devices in ultrafast electronics and optoelectronics

Proceedings of the IEEE, 1994-07, Vol.82 (7), p.1037-1059

1994

Volltextzugriff (PDF)

40-W CW broad-band spatial power combiner using dense finline arrays

IEEE transactions on microwave theory and techniques, 1999-07, Vol.47 (7), p.1070-1076

1999

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos One

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(226)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(284)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(213)
Life Sciences & Biomedicine
(153)
Humans
(144)
Female
(75)
Male
(71)
Adult
(54)
Biological And Medical Sciences
(53)
Middle Aged
(52)
Aged
(45)
Genetics & Heredity
(43)
Medical Sciences
(43)
Genome-Wide Association Study
(42)
Risk Factors
(41)
Physical Sciences
(40)
Genetic Predisposition To Disease
(33)
Fundamental And Applied Biological Sciences. Psychology
(31)
Polymorphism, Single Nucleotide
(28)
Genetic Aspects
(27)
Medicin Och Hälsovetenskap
(27)
Genetics Of Eukaryotes. Biological And Molecular Evolution
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy

112-GHz, 157-GHz, and 180-GHz InP HEMT traveling-wave amplifiers

A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression

Comparison of Neuroimaging Modalities for the Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Dementia

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Neuroimaging Results and A4 in the Context of the LEARN Study

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Architecture, design, and test of continuous-time tunable intermediate-frequency bandpass delta-sigma modulators

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE

SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER’S DISEASE DEMENTIA

SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2

A 60-watt X-band spatially combined solid-state amplifier

Reply to Pharmacokinetic Drug-Drug Interactions Between Olanzapine and Valproate Need to Be Better Studied

Active and nonlinear wave propagation devices in ultrafast electronics and optoelectronics

40-W CW broad-band spatial power combiner using dense finline arrays

Aktive Filter

Suchergebnisse filtern